Overview


According to FutureWise analysis the market for Antacids in 2023 is US$ 7.59 billion, and is expected to reach US$ 10.89 billion by 2031 at a CAGR of 4.60%.

Antacids are medicines that alleviate heartburn and indigestion by reducing stomach acid levels. They work by inhibiting the enzyme responsible for acid production during digestion (pepsin). They are usually available in two forms: liquid and chewable tablets. Antacids quickly show the results and relieve symptoms such as burning sensations in the stomach or chest, bloating or fullness, sour taste in the mouth, and mild chest or stomach pain. The majority of the population can safely take it. Still, individuals with low-sodium diets, taking other medicines, children under 12, pregnant women, people with complaints of heart failure and high blood pressure, and person with liver or kidney disease should consult their healthcare provider before use. Dosage strengths vary by age, and reason for use, and specific instructions should be followed as indicated on the product's packaging.

Active ingredients in antacids include aluminum, calcium, magnesium, and sodium salts (sodium) in forms such as alginate, aluminum hydroxide, calcium carbonate, magnesium carbonate, magnesium hydroxide, magnesium trisilicate, and sodium bicarbonate. Antacids should be taken when symptoms occur or one hour after eating if symptoms are anticipated. Regular users should consult their healthcare provider for possible underlying causes of frequent heartburn. Side effects are rare but may include constipation, diarrhea, flatulence, headache, nausea, vomiting, stomach cramps, or abdominal pain. Serious complications are more likely in infants and individuals over 65, including acid rebound, neurotoxicity, microcytic anemia, osteopenia, or hypercalcemia.

FutureWise Market Research has published a report that provides an insightful analysis of Antacids Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Antacids Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  •  AstraZeneca
  •  Bayer AG
  •  Boehringer Ingelheim GmbH
  •  Dr. Reddy’s Laboratories Ltd.
  •  GlaxoSmithKline plc
  •  Johnson and Johnson
  •  Pfizer Inc.
  •  Procter and Gamble
  •  Reckitt Benckiser Group plc
  •  Sanofi
  •  Sun Pharmaceuticals Ltd
  •  Takeda Pharmaceutical
  •  Valeant Pharmaceuticals International, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in the Antacids Market:

  • In June 2022, Zydus Lifesciences obtained the ultimate acceptance from the United States Food and Drug Administration to introduce Famotidine tablets, available in 20 and 40 mg. Famotidine, a histamine H2 receptor blocker, decreases the stomach's acid levels.
     
  • In March 2023, Wonderbelly, a company specializing in digestive remedies, introduced a trio of antacid flavors, including the exclusive Fruity Cereal variant, available only at select Target stores.

The antacid market is driven by several factors, such as the strong demand for products or services according to consumer preference, emerging markets, and population growth. Technological progress generates fresh prospects for the Antacids Market by integrating novel interventions and combinations that amplify effectiveness, ultimately driving innovation and market expansion. Increased prevalence of digestive disorders like acid reflux, heartburn, regurgitations, and indigestion is propelling the market. With the aging population, there is a natural increase in digestive problems due to reduced digestive enzyme production and slower digestion, demanding more use of antacids and fuelling the market. In addition, Government policies, incentives, and increased healthcare expenditure in many countries encourage market players to participate in more interventions, such as introducing chewable tablets, liquid forms, and flavors, which appeal to consumers and drive the market. 

Antacids also possess specific side effects and complications like other drugs, such as constipation, diarrhea, and electrolyte imbalance, which deters the affected individuals and hampers the market growth. The emergence of alternative treatment options, such as lifestyle modification, dietary adjustments, and others, can reduce the reliance on antacids, hindering the market.

By Drug Class

  •  Proton Pump Inhibitors
  •  H2 Antagonists
  •  Acid Neutralizers

By Formulation

  •  Tablets
  •  Liquid
  •  Powder
  •  Others

By Distribution Channel

  •  Hospital Pharmacies
  •  Retain Pharmacies
  •  Others

By Region

  •  North America
  •  Europe
  •  Asia-Pacific
  •  Latin America
  •  Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.
By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America is expected to grow significantly in this market due to the increasing incidence of gastroesophageal reflux diseases (GERD), lifestyle, and changes in food habits leading to GERD among the population.in addition, there is increased demand for antacids, a strong base of the healthcare industry, and expanded healthcare expenditure is fuelling the market in this region. Advancement in the antacids through thorough research and development is also driving the market in North America.

  •  Tier 1 players- established companies in the market with a major market share
  •  Tier 2 players
  •  Emerging players which are growing rapidly
  •  New Entrants

  •  Growth prospects
  •  SWOT analysis
  •  Key trends
  •  Key data-points affecting market growth

  •  To provide with an exhaustive analysis on the Antacids Market By Drug Class, By Formulation, By Distribution Channel and By Region.
  •  To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  •  To evaluate and forecast micro-markets and the overall market
  •  To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  •  To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  •  We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  •  The customization Mobility Care offered are free of charge with purchase of any license of the report
  •  You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Antacids Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antacids Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Antacids Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Antacids Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Proton Pump Inhibitors
        2. H2 Antagonists
        3. Acid Neutralizers

  • 8.   Global Antacids Market, By Formulation Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Tablets
        2. Liquid
        3. Powder
        4. Others

  • 9.   Global Antacids Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retain Pharmacies
        3. Others

  • 10.   North America Antacids Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Antacids Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Antacids Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Antacids Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. AstraZeneca
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bayer AG
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Boehringer Ingelheim GmbH
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Dr. Reddy’s Laboratories Ltd.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. GlaxoSmithKline plcr
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Johnson and Johnson
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Pfizer Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Procter and Gamble
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
            9. Reckitt Benckiser Group plc
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
         10. Sanofi
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
          11. Sun Pharmaceuticals Ltd
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
          12. Takeda Pharmaceutical
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
          13. Valeant Pharmaceuticals International, Inc.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients